Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes

Gregory J. Kato\textsuperscript{a*}, Mark T. Gladwin\textsuperscript{a}, and Martin H. Steinberg\textsuperscript{b}

\textsuperscript{a}Vascular Medicine Branch, National Heart, Lung and Blood Institute; Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Drive, Building 10CRC 5-5140, Bethesda, MD 20892-1476, U.S.A.

\textsuperscript{b}Center of Excellence in Sickle Cell Disease, E248, Boston Medical Center, 88 E Newton St, Boston, MA 02118, U.S.A.

Summary

Hemolysis, long discounted as a critical measure of sickle cell disease severity when compared with sickle vaso-occlusion, may be the proximate cause of some disease complications. New mechanistic information about hemolysis and its effects on nitric oxide (NO) biology and further examination of the subphenotypes of disease requires a reappraisal and deconstruction of the clinical features of sickle cell disease. The biology underlying clinical phenotypes linked to hemolysis may increase our understanding of the pathogenesis of other chronic hemolytic diseases while providing new insights into treating sickle cell disease.

The pathophysiological roles of dysregulated NO homeostasis and sickle reticulocyte adherence have linked hemolysis and hemolytic rate to sickle vasculopathy. Nitric oxide binds soluble guanylate cyclase which converts GTP to cGMP, relaxing vascular smooth muscle and causing vasodilatation. When plasma hemoglobin liberated from intravascularly hemolyzed sickle erythrocytes consumes NO, the normal balance of vasoconstriction:vasodilation is skewed toward vasoconstriction. Pulmonary hypertension, priapism, leg ulceration and stroke, all subphenotypes of sickle cell disease, can be linked to the intensity of hemolysis. Hemolysis plays less of a role in the vaso-occlusive-viscosity complications of disease like the acute painful episode, osteonecrosis of bone and the acute chest syndrome.

Agents that decrease hemolysis or restore NO bioavailability or responsiveness may have potential to reduce the incidence and severity of the hemolytic subphenotypes of sickle cell disease. Some of these drugs are now being studied in clinical trials.

Keywords

Sickle cell; Pulmonary hypertension; Priapism; Ulcer; Hemolysis; Nitric oxide

Introduction

Sickle cell disease, a systemic disorder whose proximate cause is a mutation in the \(\beta\)-globin chain of hemoglobin, has as its major clinical features acute episodes of pain, stroke, priapism and acute chest syndrome and chronic organ damage, like osteonecrosis, renal failure and chronic hemolytic anemia.\textsuperscript{1} Dysregulated NO homeostasis, a consequence of hemolytic anemia, may be responsible for some of the complications of sickle cell disease and other chronic forms of hemolytic anemia. This article will review the evidence for a
Nitric oxide and the hemolysis phenotype

Hemolytic anemia varies in intensity among the genotypes of sickle cell disease. It is most severe in patients with sickle cell anemia who are homozygous for the sickle hemoglobin gene mutation (HBB; glu6val), less severe in individuals with sickle cell anemia and concurrent α thalassemia (homozygous or heterozygous for a single α-globin gene (HbA1, HBA2) deletion, a genotype found in a third of individuals with sickle cell anemia, and least severe in patients with HbSC disease (compound heterozygosity for HbS and HbC (HBB; glu6lys)). Even within a single genotype, the hemoglobin concentration is variable. For example, in sickle cell anemia, 51Cr red cell survival ranges between two and 21 days and this is reflected in similarly wide variations of total hemoglobin concentration, reticulocyte count, bilirubin level and lactate dehydrogenase (LDH) levels, all clinical markers of hemolysis.2,3 Hemolytic anemia may be the driving force behind some complications of sickle cell disease because of its effects on NO bioavailability.4 Nitric oxide binds soluble guanylate cyclase, which converts GTP to cGMP, relaxing vascular smooth muscle and causing vasodilatation (Fig. 1). Plasma hemoglobin liberated from intravascularly destroyed sickle erythrocytes consumes NO, producing methemoglobin and bio-inactive nitrate. A state of reduced endothelial NO bioavailability in sickle cell disease impairs downstream homeostatic vascular functions of NO, like inhibition of platelet activation and aggregation and transcriptional repression of the cell adhesion molecules, VCAM-1, ICAM-1 (vascular cell adhesion molecule-1, intercellular adhesion molecule-1), P-selectin and E-selectin.5 Hemoglobin, heme and heme iron catalyze the production of oxygen radicals, further limiting NO bioavailability and activating endothelium.6 Lysed erythrocytes also liberate arginase that destroys L-arginine, the substrate for NO production, providing another mechanism for endothelial NO deficiency.7 Although not linked directly to hemolysis, reactive oxygen species, generated at high rates in patients with sickle cell disease, also consume NO.8,9 The normal balance of vasoconstriction to vasodilation is therefore skewed toward vasoconstriction, endothelial activation and proliferation. Both hemolytic rate and splenectomy (surgical and functional) are associated with red cell membrane damage, phosphatidyserine exposure at the red cell membrane surface, activation of tissue factor and thrombosis.10–18 Speculatively, chronic anemia and tissue ischemia might also contribute to a proliferative vasculopathy via activation of HIF-1-(hypoxia inducible factor) dependent factors such as iNOS (inducible nitric oxide synthase), erythropoietin, and VEGF (vascular endothelial growth factor), which has been seen in an animal model of pulmonary hypertension.19,20

Pulmonary hypertension and hemolysis

Pulmonary hypertension affects about 30% of patients with sickle cell anemia and is a major risk factor for near-term death.21–24 Other varieties of hemolytic anemia have also been linked to pulmonary hypertension, particularly in splenectomized patients, including beta-thalassemia intermedia and major, pyruvate kinase deficiency, and hereditary spherocytosis.11,12,25–36 Pulmonary thrombosis, a common complication of pulmonary hypertension, is seen frequently in these hemolytic disorders, especially following splenectomy.32,15,27,35,37,38 Splenectomy has been previously suspected to play a role in the development of vasculopathy in otherwise healthy patients, although this point remains controversial.39,40 In patients with thalassemia, plasma hemoglobin levels preliminarily have been reported to be higher in splenectomized patients than non-splenectomized patients.41 This remains to be confirmed and further investigated, but splenectomy removes a large portion of the reticuloendothelial system, lowering the overall hemolytic rate, possibly shifting some of the hemolysis from
extravascular to intravascular compartment. This hypothetically would liberate more plasma hemoglobin, which would lead to more intense scavenging of nitric oxide, with vasoconstrictive and prothrombotic consequences. Surgical asplenia in thalassemia and functional asplenia in sickle cell disease might also lead to prolonged circulation of abnormal red cells with cell surface phosphatidylserine, implicated in hemostatic activation in both diseases.10,11,17,42

In patients with sickle cell disease or thalassemia, markers of hemolysis are associated with indicators of reduced NO availability, endothelial dysfunction and pulmonary hypertension. Markers of hemolysis such as plasma hemoglobin and serum lactate dehydrogenase (LDH) correlate closely with nitric oxide consumption and dysregulated metabolism of arginine, the substrate of nitric oxide synthase.4,43 These markers also correlate with endothelial dysfunction manifested as abnormal vascular reactivity in forearm blood flow studies, or as elevated plasma levels of soluble endothelial adhesion molecules.43–45 Finally, serum LDH, high bilirubin and low total hemoglobin are linked to the prevalence and severity of pulmonary hypertension.22,43 Some of these same observations have been made in thalassemia intermedia and major.46

Hemolysis and the priapism paradox

Priapism has a distinctive relationship to hemolysis and pulmonary hypertension. It is one of the only complications of sickle cell disease found to be associated with pulmonary hypertension in sickle cell disease.22,43 Priapism is associated with reduced hemoglobin level and the hemolytic markers, reticulocyte count, bilirubin, LDH and aspartate aminotransferase (AST).43,47 Patients with a history of priapism have a fivefold greater risk of developing pulmonary hypertension.22 Consistent with an epidemiological link between pulmonary hypertension, priapism, and hemolytic pathobiology, priapism and pulmonary hypertension are more common in individuals with sickle cell anemia than patients with sickle cell anemia-α thalassemia or HbSC disease.7,47 Similar to pulmonary hypertension, priapism may also complicate unstable hemoglobinopathy, β thalassemia intermedia, paroxysmal nocturnal hemoglobinuria and other types of hemolytic anemia where NO scavenging by plasma hemoglobin is likely.48–55

Since NO is generally believed to play a role in normal penile erection, it is paradoxical that chronically impaired NO bioavailability is associated with priapism. For example, it is well known that increasing NO-dependent cGMP levels by inhibition of phosphodiesterase 5 (PDE5) with drugs like sildenafil increases erectile responses. However, consistent with this association, increased priapic activity is seen in the severely NO deficient double nos3/nos1 knockout mouse.56 This unexpected priapism was attributed to severe down-regulation of PDE5 due to chronic NO deficiency resulting in episodic uncontrolled cGMP-dependent vasodilation of the penile erectile tissue, presumably by activation of soluble guanylate cyclase by other non-NO dependent mediators such as CO or voltage gated signaling. Such a paradox suggests a potential beneficial effect of PDE5 inhibitors, such as sildenafil, on priapic activity.57,58 Perhaps more importantly, this pathobiology suggests that efforts to control hemolytic rate may reduce priapic activity.

Leg ulcers and hemolysis

Patients with leg ulcers had lower hemoglobin levels and higher levels of lactate dehydrogenase, bilirubin, aspartate aminotransferase and reticulocytes than did age and sex matched control patients with sickle cell anemia but without leg ulcers.59 Age-adjusted comparisons showed that sickle cell anemia-α thalassemia and HbSC disease were more frequent among controls than leg ulcer cases. These results strongly suggested that the likelihood of having leg ulcers was related to the intensity of hemolysis.43,47 Similar to
pulmonary hypertension and priapism, cutaneous leg ulcers are also seen in other forms of hemolytic anemia.60–69 The incidence of leg ulcers does not appear to be linked to frequency of vaso-occlusive crisis.59,70

Stroke and hemolysis

The evidence linking stroke to hemolysis is more circumstantial and less definitive. In several studies of stroke in sickle cell disease, stroke was associated with lower hemoglobin concentration.71 Coexistent α thalassemia protects patients with sickle cell anemia from stroke.72 Likewise, the prevalence of α thalassemia was significantly higher in children with normal transcranial Doppler (TCD) flow rates than in patients with high flow velocity, a risk factor for stroke.73 Whether this is due to the known effect of α thalassemia to reduce hemolysis and increase hemoglobin, or to some other effect of α thalassemia on the sickle erythrocyte is unknown. Supporting a link between hemolytic risk and stroke risk, in children with sickle cell disease and abnormally high TCD velocities, chronic transfusion simultaneously reduces the hemolytic rate, plasma hemoglobin level and the risk for stroke.74,75 In another study, silent cerebral infarct also was associated with lower hemoglobin, although there was no association of α thalassemia, reticulocyte count, AST or bilirubin with silent infarct.76

A self-reported history of stroke is associated with pulmonary hypertension in patients with sickle cell disease.22 In addition, we have reported a case series of six adult patients with sickle cell disease and cerebrovascular disease, with overt or sub-clinical cerebral infarcts, all of whom had pulmonary hypertension.77 All six patients shared a characteristic profile of particularly severe hemolysis seen in most sickle cell patients with pulmonary hypertension. There are many similarities in the epidemiological, physiological and histopathological features of these two complications of sickle cell disease, and it is intriguing to hypothesize that, like pulmonary hypertension, part of the pathophysiology of cerebrovascular disease might involve impaired NO bioavailability.

Fetal hemoglobin (HbF), α thalassemia and the viscosity-vaso-occlusive phenotype

High HbF levels reduce the incidence of some subphenotypes of sickle cell disease, like osteonecrosis,78 acute chest syndrome79,80 and acute painful episodes (Table 1).80,81 HbF level has not been associated with protection from pulmonary hypertension, stroke or priapism.22,47,71 This is paradoxical, since HbF expression in patients with sickle cell disease is well known to be associated with decreased overall hemolysis. The solution to the paradox may lie in the remarkably high rate of intense hemolysis in the fraction of red cells that fail to express HbF.82 In addition, potential associations of HbF with these subphenotypes may also be obscured by analytical approaches that fail to account for the interactions of many other genetic modifiers with HbF.83 The principal observed clinical benefits of HbF are on the viscosity-vaso-occlusive phenotype, potentially due to the anti-sickling effect of HbF.81

While concurrent α thalassemia also decreases hemolysis,2,84 it also is protective for the putatively hemolysis-associated phenotypes of leg ulcers,85–87 priapism47 and stroke,72,73,88 and it is associated with increased risk of the viscosity-vaso-occlusive phenotypes of acute painful episodes89–92 and osteonecrosis.85,93,94 Similarly, α thalassemia has also been associated with increased incidence of another viscosity-vaso-occlusive complication, namely the acute chest syndrome,85 although the opposite result has been seen in smaller studies or in children.87,89 In general, the phenotypic associations of α thalassemia closely mirror the associations of high hemoglobin (Table 1).
Hemolysis and the sickle reticulocyte, initiators of vaso-occlusion

Hemolysis promotes adhesive properties of circulating cells and the vessel wall. Sickle reticulocytes, increased in number in response to hemolysis, display receptors and ligands responsible for their adherence to endothelium and leukocytes. Under flow conditions, reticulocytes were the most adherent of the heterogeneous population of sickle erythrocytes.\(^95\) Reticulocyte adherence provides an additional link between hemolytic anemia and sickle vaso-occlusion. Sickle erythrocytes adhere to cultured endothelial cells and the tenacity of adherence reflects the severity of disease.\(^96,97\) Receptors and ligands for this interaction have been characterized.\(^98,99\) Sickle erythrocyte adherence also varies according to the hemoglobin genotype being most manifest in sickle cell anemia. Even among patients with this genotype, adherence varies about twenty-fold.\(^96\) Since most of the endothelial cell adhesion molecules that bind sickle reticulocytes are normally suppressed by NO, decreased NO bioavailability resulting from intravascular hemolysis might also contribute to sickle erythrocyte adherence.\(^44,100–105\)

Hemolysis in geographic subgroups

The prevalence of priapism and leg ulcers is reported to be much higher in patients with sickle cell disease in Jamaica, who manifest severe hemolysis, than those in India or Greece, in whom less severe hemolysis is seen.\(^106–108\) However, the rates of vaso-occlusive crisis and acute chest syndrome are comparable between these geographic subgroups. Although one might suspect the geographic difference in priapism and leg ulcer rates to be due to differences in fetal hemoglobin levels, in the Cooperative Study of Sickle Cell Disease conducted in the U.S.A., priapism and leg ulcers were associated with severity of hemolysis and not with fetal hemoglobin levels.\(^47,59\) This further supports the concept of a hemolysis-endothelial dysfunction subphenotype distinct from the viscosity-vaso-occlusion subphenotype.

Hemolysis and desaturation

Several groups have found an association of low transcutaneous oxygen saturation of hemoglobin with elevated serum lactate dehydrogenase, severity of anemia and reticulocytosis, suggesting a link between hemolysis and hypoxemia.\(^43,109–112\) Speculatively, this link might involve hemolysis-associated pulmonary hypertension and consequent ventilation-perfusion mismatch, although other factors may also play a role.\(^113\) Further investigation is required to understand this observation.

Hemolysis and animal models

More definitive scientific evidence has been obtained in animals showing that hemolysis causes vasomotor instability, supporting the extensive epidemiological evidence in humans. Experimentally induced hemolysis in dogs provokes systemic and pulmonary hypertension, renal dysfunction, and diminished vascular response to NO donors.\(^114\) These findings are directly associated with biochemical evidence of stoichiometric oxidation of nitric oxide by cell-free plasma hemoglobin. Furthermore, they are attenuated by administration of inhaled nitric oxide, which oxidizes cell-free plasma hemoglobin to methemoglobin, preventing its scavenging of endogenous NO. These biochemical and physiological data in a large animal model provide the strongest mechanistic evidence to date for a human syndrome of hemolysis-associated dys-regulation of NO bioactivity.

Augmenting the NO pathway in sickle cell disease

Therapies directed at restoring NO homeostasis have shown promise in preliminary studies in patients with sickle cell disease. In children with sickle cell disease presenting to the emergency
department with vaso-occlusive pain crisis, inhaled nitric oxide therapy was associated with trends toward lower pain scores, decreased analgesic requirements, and shorter hospital stay. A larger scale study is currently under way. Oral administration of the NO synthase substrate L-arginine has been effective in a pilot study of sickle cell pulmonary hypertension. Inhibition of phosphodiesterase-5 by sildenafil promotes accumulation of cGMP, amplifying the effect of NO in pulmonary vascular smooth muscle, improving hemolysis-associated pulmonary hypertension in two preliminary human trials. These therapies cannot yet be recommended until larger scale clinical trials are completed, but further research is clearly warranted in this area.

Conclusions: A new perspective on sickle subphenotypes and goals for treatment

Hemolytic and viscosity-vaso-occlusive phenotypes must have substantial areas of overlap. Nevertheless, this dichotomization helps place subphenotypes of sickle cell disease into a new context (Fig. 2). Hemolytic anemia and increased NO scavenging play a major role in the propensity to acquire the subphenotypes of pulmonary hypertension, stroke, leg ulcer and priapism. At least the latter three are ameliorated by \( \alpha \)-thalassemia that reduces hemolysis and improves anemia. HbF, while it should not be disregarded as a modulator of these subphenotypes, has little direct protective effect against these vasculopathic complications. Distinct from these phenotypes are ones associated with increased blood viscosity, like osteonecrosis, acute chest syndrome and painful episodes. Adversely affected by \( \alpha \)-thalassemia, their prevalence is directly associated with higher hemoglobin concentration and HbF has a protective effect. These data serve to support a concept of subphenotypes in sickle cell disease, as previously proposed by others.

Hemolytic anemia-induced phenotypes are likely to be improved by transfusion and agents that increase NO bioavailability or dramatically reduce hemolysis. HbF induced by hydroxyurea appears to have an anti-sickling effect that reduces the severity of viscosity-vaso-occlusive complications. However, the heterocellular HbF distribution induced by hydroxyurea may not reduce hemolysis sufficiently to correct the hemolysis-endothelial dysfunction complications. In order to significantly impact the hemolytic complications, HbF-inducing agents might have to achieve a pancellular distribution of HbF.

An increased fraction of dense cells is present in most patients with sickle cell disease and HbS polymerization is critically dependent on cell density. Drugs capable of reducing cell density are accompanied by decreased hemolysis and clinical trials of some of these agents have started. Agents that decrease hemolysis or restore NO bioavailability or the responsiveness of the vasculature to NO may have potential to reduce the incidence and severity of the hemolytic subphenotypes of sickle cell disease.

Practice Points

• Adults with sickle cell disease and thalassemia intermedia or major should be screened by echocardiogram for a tricuspid regurgitant jet velocity (TRV) \( \geq 2.5 \) m/sec, suggestive of pulmonary hypertension. Patients with elevated TRV should be referred to a pulmonologist or cardiologist knowledgeable in hemoglobinopathy-associated pulmonary hypertension.

• Clinicians should be alert to a syndrome of hemolysis-endothelial dysfunction, including high serum lactate dehydrogenase levels, pulmonary hypertension, leg ulcers and priapism.
Research Agenda

- Role of oxidant stress in reducing nitric oxide bioactivity in sickle cell disease.
- Efficacy of the endothelin receptor antagonist bosentan or phosphodiesterase-5 inhibitors in hemolysis-associated pulmonary hypertension.
- Efficacy of novel nitric oxide donors in acute and chronic sickle cell ischemic tissue injury.

Acknowledgement

Supported in part by NHLBI grants HL R01 68970, HL R01 70735 and 1U54 HL 0708819 (M.H.S.) and by intramural funding from the NHLBI and NIH Clinical Center (G.J.K. and M.T.G.). Vikki Nolan, Diego Wyszynski, John Farrell, Alice Bisbee, Lindsay Farrer and Paola Sebastiani participated in the collection and analysis of data reported from Dr. Steinberg’s laboratory.

References


70. Ballas SK. Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells. American Journal of Hematology 1991;36:122–130. [PubMed: 1707225]


101. Khan, BV.; Harrison, DG.; Olbrych, MT.; Alexander, RW.; Medford, RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells; Proceedings of the National Academy of Sciences of the United States of America; 1996. p. 9114-9119.


Figure 1.
Intravascular hemolysis reduces nitric oxide bioactivity. Nitric oxide is produced by isoforms of nitric oxide (NO) synthase, using the substrate L-arginine. Intravascular hemolysis simultaneously releases hemoglobin, arginase, and lactate dehydrogenase (LDH) from red cells into blood plasma. Cell-free plasma hemoglobin stochiometrically inactivates NO, generating methemoglobin and inert nitrate (A). Plasma arginase consumes plasma L-arginine to ornithine, depleting its availability for NO production (B). LDH also released from the red cell into blood serum serves as a surrogate marker for the magnitude of hemoglobin and arginase release. NO is also consumed by reactions with reactive oxygen species (O_2^−) produced by the high levels of xanthine oxidase activity and NADPH oxidase activity seen in sickle cell disease, producing oxygen radicals like peroxynitrite (ONOO−)(C). The resulting decreased NO bioactivity in sickle cell disease is associated with pulmonary hypertension, priapism, leg ulceration, and possibly with non-hemorrhagic stroke. A similar pathobiology is seen in other chronic intravascular hemolytic anemias.
Figure 2. Model of overlapping subphenotypes of sickle cell disease. Published data suggest that patients with sickle cell disease with higher hemoglobin levels have a higher frequency of viscosity-vaso-occlusive complications closely related to polymerization of sickle hemoglobin, resulting in erythrocyte sickling and adhesion. Such complications include vaso-occlusive pain crisis, acute chest syndrome, and osteonecrosis. In contrast, a distinct set of hemolysis-endothelial dysfunction complications involving a proliferative vasculopathy and dysregulated vasomotor function, including leg ulcers, priapism, pulmonary hypertension, and possibly non-hemorrhagic stroke, is associated with low hemoglobin levels, and high levels of hemolytic markers such as reticulocyte counts, serum lactate dehydrogenase, plasma hemoglobin and arginase, producing a state of impaired nitric oxide bioavailability. The spectrum of prevalence and severity of each of these subphenotypes overlap with each other. Patients with α-thalassemia trait tend to have less hemolysis and higher hemoglobin levels, tending to decrease the prevalence of hemolysis-endothelial dysfunction, and tending to increase the prevalence of viscosity-vaso-occlusion. The effect of fetal hemoglobin expression or chronic red cell transfusion is more complex, simultaneously increasing hemoglobin level, but reducing sickling and hemolysis.
## Table 1
Patterns of association of known prognostic factors with specific complications of sickle cell disease

<table>
<thead>
<tr>
<th>Prognostic Factor</th>
<th>Viscosity-Vaso-occlusive Subphenotype</th>
<th>Hemolysis-Endothelial Dysfunction Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>VOC</td>
<td>ACS</td>
</tr>
<tr>
<td>High LDH</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>High hemoglobin</td>
<td>↑/↑</td>
<td>↑/↑</td>
</tr>
<tr>
<td>α-thalassemia</td>
<td>↑/↑</td>
<td>↑</td>
</tr>
<tr>
<td>High HbF</td>
<td>↓/↓</td>
<td>↓/↓</td>
</tr>
<tr>
<td>Hydroxyurea</td>
<td>↓/?</td>
<td>↓/?</td>
</tr>
</tbody>
</table>

Abbreviations: VOC, vaso-occlusive pain crisis; ACS, acute chest syndrome; AVN, avascular necrosis of bone; PHT, pulmonary hypertension; LDH, serum lactate dehydrogenase; HbF, fetal hemoglobin; ↑, increased risk; ↓, decreased risk; -, no change in risk observed; ?, effect on risk has not been well evaluated. The information in this table is derived from recent reviews and other publications. More detailed information is presented in the text.

\( ^{a} \)Permissive in patients with HbSS, protective in patients with HbSC.